NKGen Biotech Inc. · OTC:NKGN
NKGen Biotech — Investor Presentation (February 2024)
36 slides from NKGen Biotech's investor presentation, February 2024
Slide 1: Maximizing Immune Integrity: SNK01 for Neurodegenerative Disease
Maximizing Immune Integrity SNK01 for Neurodegenerative Disease February 2024
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This Presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. NKGen Biotech, Inc.'s ("NKGen" or "the Company") forward-looking statements inc
Slide 3: Corporate Information
CORPORATE INFORMATION NKGen was founded in 2017 – Investment to date is 61 Full-time Employees + $114M 2 Part-time Nurses 38 GMP • NKGen merged with Graf Acquisition Corp. IV in October 2023 and listed on NASDAQ 10 Clinical Lab • Prior investments funded purchase of facility and GMP build- 3 Clinica
Slide 4: Executive Team and Board of Directors
Executive Team Sangwoo Park* Paul Y. Song, MD* James Graf Pierre Gagnon Founder & Executive CEO Chief Financial Officer Chief Operating Officer Chairman Founder of NKMAX, Korean Parent Company Yong Man Kim, PhD Ryan Park, CFA Denise Chua, MBA, CLS, Paul Chang, MPH Chief Scientific Officer SVP, Finan
Slide 5: Natural Killer Cells
Natural Killer Cells Innate Lymphoid Cells: • 5-20% of circulating lymphocytes Disease Nk Cell Activity and/or Number Surface Phenotype: Viral infection Activity & number • CD3- CD56+ Cancer Activity Rheumatoid Activity & number (blood), number Can Distinguish Non-Self/Dangerous Cells Arthritis in s
Slide 6: State-Of-The-Art GMP Manufacturing Facility
State-Of-The-Art GMP Manufacturing Facility Licensed cell therapy manufacturing facility • 25,000 sq ft facility (12,000 sq ft for GMP) completed in 2019 • CAP/CLIA Laboratory • Facility owned and operated by NKGen Biotech 6
Slide 7: NKGen's Manufacturing (CMC) Process
NKGen’s Manufacturing (CMC) Process Superior Expansion With Increased Cytotoxicity And Activating Receptor Expression NKGen can expand NK cells from any donor! Expansion Fold Expansion Fold 6000 6000 (8 Healthy Donors) (11 Cancer Patients) 5060 NK cell Expansion 5022 4000 4000 3915 activating FOLD (
Slide 8: Autologous Next Gen Manufacturing
Autologous Next Gen Manufacturing NKGen “Off-the-Shelf Autologous” SNK Cell Therapy Superior Cell Our Expansion and Cryoprocess Activation preserves cell features Auto-SNK No Lymphodepletion 1 2 3 5 4 5 Collect Isolate Activate & Expand Cryopreserve Deliver to Clinic Thaw and Administer Leukapheresi
Slide 9: SNK01: Alzheimer's and Parkinson's Diseases
SNK01 Alzheimer’s and Parkinson’s Diseases 9
Slide 10: Market Opportunity in Neurodegenerative Disease
Market Opportunity in Neurodegenerative Disease NKGen’s SNK01, not yet FDA approved, will seek to address a multi-billion/year market Over 55 million people Alzheimer’s We are aware of no therapies worldwide had dementia in and Parkinson’s currently 2023, with a new case patients are estimated to on
Slide 11: Case Studies
Case Studies 11
Slide 12: Compassionate Case Study #1 - PSEN1 Mutation and Advanced Alzheimer's
Compassionate Case Study # 1 - 38 Y.O. With PSEN1 Mutation And Advanced Alzheimer’s Treated With SNK01 IMPRESSION: Striking decreased parietal activity with moderate diffuse temporal, occipital and posterior fossa activity. RESULTS AND INTERPRETATIONS: This patient is heterozygous in the PSEN1 gene
Slide 13: Compassionate Use Case Study #2 - 70 Y.O. With Advanced Alzheimer's
Compassionate Use Case Study # 2 – 70 Y.O. With Advanced Alzheimer’s Treated With SNK01 Technical Results: Aβ42 369.1 pg/ml Patient was originally diagnosed in 2016 at Columbia University Medical Center with Advanced Alzheimer’s Disease. T-Tau 692.6 pg/ml P-Tau 83.5 pg/ml ATI 0.35 Patient received 6
Slide 14: Patient Granted Single Compassionate Use IND Approval By FDA
Patient Was Granted Single Compassionate Use IND Approval By US FDA To Resume SNK01 Treatment Patient resumed treatment on 1/27/2023 and continues to be treated monthly, to date, at the Neurologic Associates of Long Island Clinic under the care of Dr. Vincent DeOrchis. Currently plan to treat patien
Slide 15: Parkinson's Compassionate Use Case Study
Parkinson’s Compassionate Use Case Study # 1 : Qualitative Evaluation Of 47 Y.O. After Treatment with SNK01 Patient was independently seen and evaluated by Dr. Ming Guo (at UCLA Medical Center) 60% Mental sharpness/reaction Fatigue/energy Percent Improvement from Baseline 50% Speech 40% Left Leg Mov
Slide 16: Phase I Data
Phase I Data 16
Slide 17: Phase I Data Presented At The 2023 CTAD Meeting
Phase I Data Presented At The 2023 CTAD Meeting No observed SAEs or dose limiting toxicity 17
Slide 18: Data From SNK01 Phase I Alzheimer's Trial
Data From SNK01 Phase I Alzheimer’s Trial Dose Response Observed for Several CSF Biomarkers Following SNK01 Treatment • Decreases were observed across several protein biomarkers related to Alzheimer’s pathology. • Reductions across several neuroinflammatory markers, including GFAP, were also observe
Slide 19: Changes In Cognitive Function Post SNK01 Treatment
Changes In Cognitive Function Post SNK01 Treatment Data From MX04 Phase I Trial Cognitive assessments at week 22 (12 weeks post last dose) Week 22 - All Patients compared to week 11; By dose cohort 10 9 CDR-SB ADAS-Cog MMSE 8 7 10 No. of patients 9 6 8 No. of patients 5 7 6 4 5 3 4 2 3 2 1 1 0 0 CDR
Slide 20: Phase I Clinical Trial Patient #15 With Alzheimer's Treated With SNK01
Phase I Clinical Trial Patient #15 85 Y.O. With Alzheimer's Disease Treated With SNK01 Patient MMSE Score Increased From 14 to 22 Subject 015. His walk was unsteady, and he couldn't dance prior to treatment. He was much more coordinated, could now dance, and was mentally sharper after treatment. See
Slide 21: Alzheimer's Disease Composite Score (ADCOMS)
Alzheimer’s Disease Composite Score (ADCOMS) A composite of the Clinical Dementia SNK01 Alzheimer’s Phase I Trial Rating (CDR) scale in its ‘sum of boxes’ incarnation (CDR-sb),with the addition of four memory ADAS-cog (Delayed Word Recall, Orientation, Word Finding Difficulty & Word Recognition), ma
Slide 22: FDA Clearance of IND for SNK01 in Alzheimer's Disease
cy BioSpace’ NkKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNKO1 NK Cell Therapy to Treat Alzheimer’s Disease Published: Oct 24, 2023 NKGen’s neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by ye
Slide 23: SNK01 For Alzheimer's Disease - Recent News
SNK01 For Alzheimer’s Disease - Recent News 23
Slide 24: Neurodegenerative Scientific Advisory Board
Neurodegenerative Scientific Advisory Board Craig Blackstone, M.D., Ph.D. Ming Guo, M.D., Ph.D. Anthony T. Reder, M.D. • Chief of Movement Disorders Division • P. Gene & Elaine Smith Chair in Professor of Neurology at at Massachusetts General Hospital Alzheimer’s Disease Research, UCLA UChicago Me
Slide 25: 2024 Clinical Milestones Timeline
2024 Clinical Milestones Timeline Phase IIa 3-Month Interim Data Phase I DLT Assessment Phase IIa begins AAIC Annual Meeting AAIC Abstract Submission Phase I IND Submission ASCO Annual Meeting Phase I Combination with ICI ASCO Abstract Last Patient, Submission Last Visit Phase I Q1 Q2 Q3 Q4 2024 202
Slide 26: SNK01 - Mechanism of Action in Neurodegenerative Disease
SNK01 – Mechanism of Action in Neurodegenerative Disease 26
Slide 27: Autoreactive T cells Cause Neuroinflammation And Damage
Autoreactive T cells Cause Neuroinflammation And Damage Chronic protein deposition leads to an autoinflammatory cascade and damage Removing proteins only addresses one aspect of the underlying pathology Activation of Autoreactive CD4+ and CD8+ T cells1-5 which migrate to the brain via CXCR36 1. Lind
Slide 28: Autoreactive T cells And SNK01 Cross BBB Via CXCR3
Autoreactive T cells And SNK01 Cross BBB Via CXCR3 SNK01 Has High CXCR3 Expression And Strong Migration Potential CXCR3 Expression CXCR3+ T cells migrate to CXCL10 positive astrocytes that frequently are associated with amyloid deposits.1 CXCR3 was highly expressed on a subpopulation of neurons and
Slide 29: NK Cells Regulate Autoreactive T cells
NK Cells Regulate Autoreactive T cells1-4 SNK01 Has Enhanced NKG2D and DNAM-1 Expression DNAM-1 M Tube_007 P1 5 UL UR 10 0.49 99.40 4 10 CD56 3 10 FITC A 2 10 LL LR 0 2 0.03 0.08 -10 -10 2 0 10 2 10 3 10 4 10 5 PerCP-Cy5.5-A DNAM-1 NKG2D 1. Rabinovich - J Immunol (2003) 170 (7): 3572–3576. 2. Lu - I
Slide 30: Weak Or Deficient NK Cells Common In Autoimmune Disease
Weak Or Deficient NK Cells Common In Autoimmune Disease Evidences of NK cell involvement in immune-mediated diseases as emerging from experimental models and human diseases1 Human diseases Disease Murine models (NK Depletion) Peripheral blood Tissue Site Rheumatoid Arthritis Protective/promoting Red
Slide 31: NK Cells Play a Protective Role in Protein Deposition
NK Cells Play a Protective Role in Protein Deposition Knockout/Depletion of NK cells in both models caused rapid acceleration of protein deposition 1. Earls RH, Menees KB, Chung J, et al. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-s
Slide 32: SNK01 Can Reduce Amyloid, p-Tau, Alpha-Synuclein, and Neuroinflammation
SNK01 Can Reduce Amyloid, p-Tau, Alpha-Synuclein, and Neuroinflammation NK cells have been found to prevent and reduce protein accumulation1,2 NK cells have also been found to identify and degenerate intact sensory axons after nerve injury3 1. Earls - PNAS - January 2020 117 (3) 1762-1771. 2. Marsh
Slide 33: Thank you
Thank you
Slide 34: Medscape News: Enhanced Natural Killer Cell Therapy Shows Promise in Alzheimer's
News > Medscape Medical News > Conference News > CTAD 2023 Enhanced Natural Killer Cell Therapy Shows Promise in Alzheimer's Megan Brooks November 02, 2023 Medscape SNKO1, being developed by NKGen Biotech, is an autologous, nongenetically modified NK cell product that has enhanced cytotoxicity and a
Slide 35: References For Neurodegenerative Disease
References For Neurodegenerative Disease • Zhou, Y-Q, et al. (2019). The role of CXCR3 in Neurological Diseases. Curr Neuropharmacol, 17(2): 142-150. • Marsh, S.E., et al. (2016). The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc Natl Acad
Slide 36: References Neurodegenerative Disease (Cont.)
References Neurodegenerative Disease (Cont.) • Earls, R.H., et al., (2020). NK cells clear alpha-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of alpha- synucleinopathy. Proc Natl Acad Sci U S A, 117(3):1762-1771. • Rabinovich, B.A., et al. (2003). Activate
NKGen Biotech — Investor Presentation (February 2024) on 6ix